This promising therapeutic , ALX0061, is a monoclonal protein currently under research development for the therapy of multiple inflammatory disorders. Importantly, it binds to interleukin-13 (IL-13), a https://vobarilizumab-autoimmune911849.wikiannouncement.com/user